Risk Stratification of Myelodysplastic Syndromes - Is There Room for Improvement?

被引：0
|
作者：
Marques, Barbara Almeida [1 ,2 ,3 ,4 ,5 ]
Silva, Duarte Pacheco [5 ]
Santos, Joao Gaiao [5 ]
Moura, Pedro Pinho [5 ]
Ana Teresa Simoes, Catia Almeida [5 ]
Oliveira, Ana Catarina [5 ]
Coucelo, Margarida [5 ]
Cortesao, Emilia [1 ,2 ,6 ,7 ,8 ]
Geraldes, Catarina [1 ,2 ,4 ,5 ,7 ,8 ]
机构：
[1] Univ Coimbra, Lab Oncobiol & Hematol, Fac Med, Coimbra, Portugal
[2] Univ Coimbra, Univ Clin Hematol, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Res Grp Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal
[4] Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
[5] Ctr Hosp & Univ Coimbra, Clin Hematol Dept, Coimbra, Portugal
[6] Ctr Hosp & Univ Coimbra, Coimbra, Portugal
[7] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Area Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal
[8] Clin Acad Ctr Coimbra, Coimbra, Portugal
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-169960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12319 / 12320
页数：2
相关论文
共 50 条
  • [31] RISK FACTORS IN MYELODYSPLASTIC SYNDROMES
    Villa, M. R.
    Gagliardi, A.
    Cuccurullo, R.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 615 - 615
  • [32] Lower risk myelodysplastic syndromes
    Angelucci, E.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 44 - 44
  • [33] Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes
    Meunier, Mathieu
    Ancelet, Sarah
    Lefebvre, Christine
    Arnaud, Josiane
    Garrel, Catherine
    Wang, Yan
    Faure, Patrice
    Polack, Benoit
    Cahn, Jean-Yves
    Park, Sophie
    BLOOD, 2016, 128 (22)
  • [34] MECHANISMS OF IMPROVEMENT OF ERYTHROPOIESIS WITH LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES
    Meunier, M.
    Ancelet, S.
    Lefebvre, C.
    Arnaud, J.
    Garrel, C.
    Wang, Y.
    Faure, P.
    Moulis, J. M.
    Polack, B.
    Cahn, J. Y.
    Park, S.
    LEUKEMIA RESEARCH, 2017, 55 : S124 - S124
  • [35] Myelodysplastic Syndromes/Neoplasms-Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
    Rose, Michal G.
    Zeidan, Amer M.
    CANCER JOURNAL, 2023, 29 (03): : 109 - 110
  • [36] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    A M Zeidan
    M A Sekeres
    G Garcia-Manero
    D P Steensma
    K Zell
    J Barnard
    N A Ali
    C Zimmerman
    G Roboz
    A DeZern
    A Nazha
    E Jabbour
    H Kantarjian
    S D Gore
    J P Maciejewski
    A List
    R Komrokji
    Leukemia, 2016, 30 : 649 - 657
  • [37] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    Zeidan, A. M.
    Sekeres, M. A.
    Garcia-Manero, G.
    Steensma, D. P.
    Zell, K.
    Barnard, J.
    Ali, N. A.
    Zimmerman, C.
    Roboz, G.
    DeZern, A.
    Nazha, A.
    Jabbour, E.
    Kantarjian, H.
    Gore, S. D.
    Maciejewski, J. P.
    List, A.
    Komrokji, R.
    LEUKEMIA, 2016, 30 (03) : 649 - 657
  • [38] Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
    Cazzola, Mario
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 349 - 352
  • [39] What constitutes meaningful improvement in myelodysplastic syndromes?
    Chandhok, Namrata S.
    Sekeres, Mikkael A.
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2528 - 2535
  • [40] Application of Next Generation Sequencing for Prognostic Stratification in Myelodysplastic Syndromes
    Xu, Yuanyuan
    Li, Yan
    Hou, Guangyuan
    Chen, Chongjian
    Yu, Li
    BLOOD, 2016, 128 (22)
12345